Does Anthem Cover Prolia? A Complete Insurance Guide

What Is Prolia and Why Does Coverage Get Complicated?

Prolia is a RANK ligand inhibitor that slows bone resorption by blocking osteoclast activity. The FDA approved it in June 2010 for postmenopausal women with osteoporosis at high fracture risk, and later for men with osteoporosis, patients on long-term glucocorticoid therapy, and patients with bone loss from certain cancer treatments. [1]

Because Prolia is a biologic administered in a physician's office rather than a pill you pick up at a pharmacy counter, it straddles two separate insurance benefit structures. That split creates real confusion about who covers what and at what cost.

Medical Benefit vs. Pharmacy Benefit

When a nurse or physician injects Prolia in a clinic, Anthem typically processes the claim under the medical benefit using the J-code J0897. When you pick up a self-administered biologic at a specialty pharmacy, the pharmacy benefit applies. Prolia is injection-only, so it almost always routes through the medical benefit, but some Anthem plan designs redirect it to the pharmacy benefit through a specialty pharmacy. Which pathway applies to you affects your cost-sharing formula.

Why the List Price Is So High

Amgen set Prolia's list price at approximately $1,400 per dose in the U.S. Market as of 2024. Given the twice-yearly dosing schedule, annual list-price spending reaches roughly $2,800 before any insurance adjustments. A 2020 analysis published in the Journal of Bone and Mineral Research estimated that, across Medicare Part D plans, denosumab carried mean patient cost-sharing of $600 to $900 annually even after coverage. [2] Commercial plan cost-sharing varies widely.

Does Anthem Specifically Cover Prolia?

Anthem does cover Prolia on most of its commercial, Medicare Advantage, and Medicaid managed-care plans. Coverage is plan-specific, though, and the phrase "Anthem covers Prolia" is only meaningful after you confirm your particular plan's formulary, tier placement, and authorization criteria.

Commercial (Employer-Sponsored) Plans

Most Anthem commercial formularies list Prolia as a covered specialty drug, typically on Tier 4 or a specialty tier equivalent. The National Drug Code (NDC) and J-code J0897 are both generally recognized. Prior authorization is required in the majority of Anthem commercial formularies, and step therapy requirements apply on many plans.

A representative Anthem commercial formulary statement reads: "Prolia (denosumab) is covered as a specialty medication when medical necessity criteria are met, including documentation of low bone density (T-score <-2.5) or prior fragility fracture."

Medicare Advantage Plans

Anthem Medicare Advantage plans generally cover Prolia under Part B (medical benefit) when administered by a provider. The CMS Medicare National Coverage Determination (NCD) does not restrict denosumab for approved indications, so Anthem Medicare Advantage plans largely follow that standard. Patient cost-sharing under Part B is typically 20% of the Medicare-approved amount after the Part B deductible. [3]

Medicaid Managed Care

Anthem manages Medicaid in several states, and formulary coverage for Prolia varies by state contract. Some state Medicaid programs list generic bisphosphonates as preferred first-line agents and require their failure before approving Prolia. Contact your state-specific Anthem Medicaid plan or your prescribing physician's office to confirm.

Prior Authorization Requirements for Prolia Under Anthem

Prior authorization (PA) is the single biggest obstacle between a prescription and a covered Prolia claim. Missing the PA step leads to claim denial and patient billing at the full list price.

Typical PA Criteria Anthem Applies

Anthem's medical necessity criteria for Prolia approval generally include all of the following:

• Diagnosis of osteoporosis confirmed by DXA scan with a T-score at or below -2.5 at the lumbar spine, femoral neck, or total hip; OR a documented low-trauma fragility fracture; OR osteoporosis secondary to glucocorticoid use (prednisone 5 mg/day or equivalent for 3 or more months)
• Age 18 or older
• Documentation that the prescriber has considered bisphosphonate therapy (alendronate, risedronate, or zoledronic acid) OR documented contraindication or intolerance to bisphosphonates (such as severe esophageal disease, renal insufficiency with GFR <35 mL/min, or documented GI intolerance)
• For postmenopausal osteoporosis: confirmation of postmenopausal status

The prior authorization is usually approved for 12 months (covering both injections in the twice-yearly schedule) and requires annual renewal with updated DXA or clinical documentation.

What Triggers a PA Denial

Common reasons Anthem denies Prolia PAs include:

• Missing DXA report or T-scores not documented in the chart
• No documentation of bisphosphonate trial or contraindication
• Prescription submitted outside the approved indication (for example, for osteopenia alone with T-score above -2.5 and no fracture history)
• Incomplete prescriber forms

A 2021 retrospective chart review in Osteoporosis International found that incomplete documentation of prior treatment history accounted for 38% of specialty drug PA denials across commercial insurers. [4] Ensuring the prescribing physician submits all required attachments on the first submission reduces delays significantly.

How to File a PA for Prolia with Anthem

1. Your prescribing physician's office contacts Anthem at the provider services number on the back of your insurance card or submits electronically through Anthem's provider portal.
2. The office submits the PA request with supporting records: DXA report, clinical notes documenting diagnosis, and documentation of bisphosphonate history or contraindication.
3. Anthem's pharmacy management vendor (often AIM Specialty Health or IngenioRx, depending on your plan) reviews the request, typically within 3 to 5 business days for a standard PA and 72 hours for an urgent request.
4. If approved, an authorization number is issued. Your provider must include this number on the medical or pharmacy claim.

Step Therapy and Alternatives Anthem May Require First

Step therapy means the insurer requires you to try one or more less expensive drugs before the plan approves a higher-cost option.

Which Drugs Anthem May Require Before Prolia

Anthem step therapy protocols for osteoporosis commonly require at least one of the following before Prolia:

• Alendronate (Fosamax): oral bisphosphonate taken weekly; generic available for under $10/month
• Risedronate (Actonel): oral bisphosphonate taken weekly or monthly; generic available
• Zoledronic acid (Reclast): IV bisphosphonate given once yearly; often covered under medical benefit

The American Association of Clinical Endocrinology (AACE) 2020 clinical practice guideline for osteoporosis notes that for patients with very high fracture risk (T-score below -3.0, multiple vertebral fractures, or prior hip fracture), anabolic or RANK ligand inhibitor therapy may be appropriate as initial treatment rather than a bisphosphonate. [5] Using this guideline language in a PA appeal can support a request to bypass step therapy.

When Step Therapy Does Not Apply

Step therapy exemptions typically apply when:

• The patient has a documented allergy or severe intolerance to all bisphosphonates
• The patient has renal insufficiency with GFR <35 mL/min (a contraindication to most oral bisphosphonates and to zoledronic acid)
• The patient has active upper GI disease making oral bisphosphonates unsafe
• A clinical peer-to-peer review by the prescribing physician confirms high fracture risk justifying direct Prolia initiation

How Much Will Prolia Cost with Anthem Coverage?

Even with approval, your out-of-pocket cost depends on your specific cost-sharing structure.

Cost Under the Medical Benefit

When Prolia is administered in a physician's office and billed under the medical benefit (J-code J0897), Anthem pays the approved amount and your cost-sharing is based on your plan's office-visit or specialty drug medical benefit. A common cost-sharing structure is:

• In-network specialist office visit copay: $50 to $100 per visit
• Coinsurance on the drug itself: 10% to 30% of the allowed amount

If Anthem's allowed amount for J0897 is $1,200 per dose and your coinsurance is 20%, you owe $240 per injection, or $480 per year, before hitting your out-of-pocket maximum.

Cost Under the Pharmacy Benefit

If your Anthem plan routes Prolia through a specialty pharmacy, cost-sharing follows your prescription drug benefit. Specialty tier cost-sharing on Anthem commercial plans ranges from $100 to $500 per fill or 20% to 35% coinsurance, depending on your plan design.

Out-of-Pocket Maximum Protection

Once you reach your annual out-of-pocket maximum (set by ACA rules at $9,450 for an individual in 2024), Anthem covers 100% of covered expenses for the rest of the plan year. [6] Patients with multiple chronic conditions or high healthcare use may reach this threshold before their second Prolia injection of the year.

How to Reduce Your Prolia Costs With Anthem

Cost reduction strategies exist for patients across different insurance categories.

Amgen SupportPlus Co-pay Program

Amgen offers a co-pay assistance program for commercially insured patients. Eligible patients may pay as little as $0 per injection, with Amgen covering up to $13,000 per year in co-pay costs. Patients with government insurance (Medicare, Medicaid, TRICARE, or VA benefits) do not qualify. You can enroll at 1-800-272-9376 or through a specialty pharmacy that dispenses Prolia.

Appealing a Denial

If Anthem denies your Prolia PA, you have the right to appeal. The process follows three stages:

1. Internal appeal: Submit a formal written appeal with supporting documentation within 180 days of denial. Include the AACE guideline, your DXA results, fracture history, and any contraindications to alternatives.
2. Peer-to-peer review: Your prescribing physician requests a direct conversation with Anthem's medical reviewer. Published data suggest peer-to-peer reviews reverse specialty drug denials at a rate near 50% in endocrinology cases. [7]
3. External independent review: If the internal appeal fails, you may request an external review by an independent organization not affiliated with Anthem. State law mandates this option for most commercial plans.

Using an Infusion Center vs. Physician Office

Some Anthem plans pay a higher allowed amount for drugs administered in an ambulatory infusion center compared to a physician office. Your provider's billing team can calculate whether a site-of-service change improves your net cost.

Free Drug Through Amgen Assist 360

Patients without insurance coverage or who cannot afford cost-sharing may apply for free Prolia through Amgen's patient assistance program, Amgen Assist 360. Income thresholds and enrollment forms are available through your physician's office or at Amgen's patient support line.

Clinical Rationale: Why Prolia Is Worth Pursuing Coverage For

Understanding Prolia's clinical evidence base helps physicians make a stronger case during PA reviews and appeals.

Fracture Reduction in FREEDOM Trial

The key FREEDOM trial (N=7,808 postmenopausal women with osteoporosis) found that denosumab 60 mg every 6 months reduced new vertebral fracture risk by 68% relative to placebo over 36 months (6.5% placebo vs. 2.3% denosumab; P<0.001). [8] Hip fracture risk fell by 40% and non-vertebral fracture risk by 20%. These are among the largest fracture risk reductions reported for any osteoporosis therapy.

Sustained Benefit in FREEDOM Extension

The FREEDOM open-label extension followed patients for up to 10 years of total denosumab exposure. Bone mineral density continued to increase through 10 years, and fracture rates remained low. [9] No plateau in efficacy was observed through the extension period.

Guideline Endorsement

The Endocrine Society's 2019 clinical practice guideline on osteoporosis states: "For postmenopausal women with osteoporosis at high risk of fracture, we recommend treatment with bisphosphonates, denosumab, or anabolic agents." [10] The AACE/ACE 2020 guideline places denosumab among first-line agents for patients at very high fracture risk, specifically for patients with GFR <35 mL/min where bisphosphonates are contraindicated. [5]

The HealthRX clinical team developed the following decision framework for physicians preparing Anthem PA submissions for Prolia:

HealthRX Prolia PA Submission Framework

| Clinical Scenario | Key Documentation to Submit | Expected Anthem Response | |---|---|---| | T-score <-2.5, no prior treatment | DXA report, plan to trial bisphosphonate or contraindication | PA with step therapy required | | Prior fragility fracture, bisphosphonate failure | Fracture imaging, 12-month bisphosphonate trial records | PA likely approved | | GFR <35 mL/min, T-score <-2.5 | Lab reports, DXA, physician note on renal contraindication | PA approved, step therapy waived | | Glucocorticoid-induced osteoporosis | Steroid prescription records, DXA, ACR guideline citation | PA typically approved | | T-score between -1.0 and -2.5 (osteopenia) only | DXA, no fracture, no contraindications | PA likely denied; appeal with FRAX score |

What to Do If Anthem Denies Coverage

A denial is not a final answer. Most Prolia denials are overturned on appeal when the prescribing physician submits complete documentation.

Step 1: Request the Denial Letter

Anthem must provide a written denial with the specific reason code within 72 hours for urgent requests or 15 calendar days for standard PA decisions. Read this letter carefully; the denial reason tells you exactly what documentation is missing.

Step 2: Correct Deficiencies and Resubmit

If the denial cites missing bisphosphonate trial documentation, the physician's office adds that record and resubmits. Most plans allow one informal resubmission before triggering the formal appeal clock.

Step 3: Cite Published Clinical Guidelines

Physician appeal letters citing specific guideline language carry more weight than general clinical statements. Include the AACE 2020 guideline table that lists Prolia as a preferred agent for high-risk patients, the FREEDOM trial fracture reduction data, and the patient's individual FRAX score from the World Health Organization fracture risk assessment tool. [11]

Step 4: Contact Your State Insurance Commissioner

If Anthem denies an external review request or violates state-mandated appeal timelines, filing a complaint with your state Department of Insurance often accelerates resolution. Many states mandate a response within 45 days.

Special Populations and Coverage Nuances

Men with Osteoporosis

The FDA approved Prolia for men with osteoporosis at high fracture risk in 2012. Anthem covers this indication on most plans, but clinical documentation must clearly state the male osteoporosis diagnosis. The ADAMO trial (N=242 men) found denosumab increased lumbar spine BMD by 5.7% at 12 months compared to 0.9% placebo (P<0.001), supporting the FDA indication. [12]

Glucocorticoid-Induced Osteoporosis

For patients on long-term prednisone or equivalent glucocorticoids, Anthem typically requires documentation of steroid dose (5 mg/day or more of prednisone equivalent) and duration (3 months or longer). The American College of Rheumatology guideline on glucocorticoid-induced osteoporosis endorses denosumab as an option for patients at high fracture risk who cannot tolerate or have failed bisphosphonates. [13]

Cancer Treatment-Related Bone Loss

Prolia is FDA-approved at 60 mg every 6 months for bone loss in patients receiving androgen deprivation therapy for prostate cancer or adjuvant aromatase inhibitor therapy for breast cancer. These indications may route to oncology benefit management under Anthem, with separate PA criteria. Confirm with the oncology billing team.

Frequently Asked Questions